Mutations in the cancer-related genes BRCA1/2 occur frequently in patients with breast, ovarian, prostate and pancreatic cancer. ACTBRCA™ detects those mutations, and the test results help you to find an effective targeted therapy.

Analyzes the genes BRCA1/2 to provide a better treatment strategy. BRCA1/2 mutations increase the risk of developing breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer. ACTBRCA™ can help these cancer patients to identify mutations in BRCA1/2, and help to provide treatment strategies. ACTBRCA™ uses NGS to detect multiple genetic mutation types in BRCA1/2

ACTBRCA™ is most suitable for patients who are

■ Breast Cancer Patients

■ Ovarian Cancer Patients

■ Prostate Cancer Patients

■ Pancreatic Cancer Patients


Sample types:

Typical tissue samples include FFPE (formalin-fixed and paraffin-embedded) tissue, and blood.

Turnaround time:

14 calendar days after samples are received